Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Trident LifelineBOM:543616 +1.55%74 EBITDA Margin % is 26.95% as of Jun. 2026, which is 18% above its 10-year median of 22.93. GuruFocus rates BOM:543616 with a GF Score™ of 74/100 and a GF Value™ of ₹606.47 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 662 Healthcare Providers & Services companies, Trident Lifeline ranks better than 89.12% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Trident Lifeline's EBITDA for the
three
months ended in Jun. 2026 was ₹91 Mil. Trident Lifeline's Revenue for the
three
months ended in Jun. 2026 was ₹337 Mil. Therefore, Trident Lifeline's EBITDA margin for the quarter that ended in Jun. 2026 was 26.95%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Trident Lifeline EBITDA Margin % Related Terms
Trident Lifeline EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Trident Lifeline's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Trident Lifeline's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trident Lifeline EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Trident Lifeline's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Trident Lifeline's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trident Lifeline (BOM:543616) has a EBITDA Margin % of 26.95% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Trident Lifeline and its competitors. This is 18% above median its historical median of 22.93. According to the industry distribution chart, Trident Lifeline ranks #72 out of 662 companies in the Healthcare Providers & Services industry, placing it in the top 10.9%.
Is Trident Lifeline's EBITDA Margin % too high?
Trident Lifeline's current EBITDA Margin % of 26.95% is 18% above median its 10-year median of 22.93. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. Trident Lifeline's value of 26.95% is 163.3% above this industry median. Based on the distribution chart, Trident Lifeline ranks #72 out of 662 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Trident Lifeline has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trident Lifeline's EBITDA Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Trident Lifeline ranks #72 out of 662 companies for EBITDA Margin %. This places Trident Lifeline in the top 11% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.24. Trident Lifeline's value of 26.95% is 163.3% above this benchmark. While the company's 10-year median is 22.93 vs. the industry median of 10.24, Trident Lifeline has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Trident Lifeline's current EBITDA Margin % of 26.95% is 163.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Trident Lifeline and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trident Lifeline's current EBITDA Margin % is 26.95%, which is 18% above median its own 10-year median of 22.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trident Lifeline stock overvalued right now?
Based on GuruFocus' analysis, Trident Lifeline (BOM:543616) is currently considered Possible Value Trap. The stock's GF Value™ is ₹606.47, compared to a current price of ₹258.45 — trading 57.4% below its estimated fair value. The current EBITDA Margin % is 26.95%, which is 18% above median its 10-year median of 22.93 and 163.3% above the Healthcare Providers & Services industry median of 10.24. Trident Lifeline's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Trident Lifeline (BOM:543616), the current EBITDA Margin % is 26.95% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Trident Lifeline (BOM:543616) Overvalued in 2026?
Based on GuruFocus' analysis, Trident Lifeline stock appears to be undervalued.
The current stock price of ₹258.45 is trading 57.4% below its estimated GF Value™ of ₹606.47.
GuruFocus considers Trident Lifeline to be Possible Value Trap.
Key valuation signals for BOM:543616:
EBITDA Margin %: 26.95% (18% above median its 10-year median of 22.93)
GF Value™: ₹606.47 vs. price of ₹258.45 (57.4% below fair value)
Industry Position: 163.3% above the Healthcare Providers & Services median (#72 of 662)
No single metric tells the full story. See the BOM:543616 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Trident Lifeline Ltd is engaged in the marketing of pharmaceutical products in domestic as well as international market. The company is also engaged in distribution of pharmaceutical products through third-party distribution network. It also offers a wide range of pharmaceutical formulations and products manufactured on contract manufacturing under a loan license. The Company's reportable geographical segments include India, Ghana, Kenya, Peru, Cameroon, Venezuela, and the Rest of World.
74GF Score
Get the complete analysis for BOM:543616
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543616 has been successfully added to your 
